Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease.

ABSTRACT:

Background

This study evaluated the potential of plasma metabolites as novel biomarkers for secondary major adverse cardiovascular event (MACE) development and risk prediction in patients with coronary artery disease.

Methods

We analyzed data from 10 175 UKB (UK Biobank) participants with coronary artery disease and metabolites (n=249) measured through nuclear magnetic resonance at baseline. Cross-validated elastic net regression models were used in the training cohort (n=7122) to select metabolites to be included in the metabolomic risk score (MRS). Hazard ratios (HRs) were estimated to examine the association between MRS and MACEs (composite of nonfatal myocardial infarction, ischemic stroke, and cardiovascular death) in the testing cohort (n=3053). Predictive performance

SUBMITTER: Osei J 

PROVIDER: S-EPMC12684584 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature